EBUS versus EUS-B for diagnosing sarcoidosis: The International Sarcoidosis Assessment (ISA) randomized clinical trial.


Journal

Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368

Informations de publication

Date de publication:
02 2022
Historique:
revised: 15 09 2021
received: 21 04 2021
accepted: 12 10 2021
pubmed: 19 11 2021
medline: 7 4 2022
entrez: 18 11 2021
Statut: ppublish

Résumé

Endosonography with intrathoracic nodal sampling is proposed as the single test with the highest granuloma detection rate in suspected sarcoidosis stage I/II. However, most studies have been performed in limited geographical regions. Studies suggest that oesophageal endosonographic nodal sampling has higher diagnostic yield than endobronchial endosonographic nodal sampling, but a head-to-head comparison of both routes has never been performed. Global (14 hospitals, nine countries, four continents) randomized clinical trial was conducted in consecutive patients with suspected sarcoidosis stage I/II presenting between May 2015 and August 2017. Using an endobronchial ultrasound (EBUS) scope, patients were randomized to EBUS or endoscopic ultrasound (EUS)-B-guided nodal sampling, and to 22- or 25-G ProCore needle aspiration (2 × 2 factorial design). Granuloma detection rate was the primary study endpoint. Final diagnosis was based on cytology/pathology outcomes and clinical/radiological follow-up at 6 months. A total of 358 patients were randomized: 185 patients to EBUS-transbronchial needle aspiration (EBUS-TBNA) and 173 to EUS-B-fine-needle aspiration (FNA). Final diagnosis was sarcoidosis in 306 patients (86%). Granuloma detection rate was 70% (130/185; 95% CI, 63-76) for EBUS-TBNA and 68% (118/173; 95% CI, 61-75) for EUS-B-FNA (p = 0.67). Sensitivity for diagnosing sarcoidosis was 78% (129/165; 95% CI, 71-84) for EBUS-TBNA and 82% (115/141; 95% CI, 74-87) for EUS-B-FNA (p = 0.46). There was no significant difference between the two needle types in granuloma detection rate or sensitivity. Granuloma detection rate of mediastinal/hilar nodes by endosonography in patients with suspected sarcoidosis stage I/II is high and similar for EBUS and EUS-B. These findings imply that both diagnostic tests can be safely and universally used in suspected sarcoidosis patients.

Sections du résumé

BACKGROUND AND OBJECTIVE
Endosonography with intrathoracic nodal sampling is proposed as the single test with the highest granuloma detection rate in suspected sarcoidosis stage I/II. However, most studies have been performed in limited geographical regions. Studies suggest that oesophageal endosonographic nodal sampling has higher diagnostic yield than endobronchial endosonographic nodal sampling, but a head-to-head comparison of both routes has never been performed.
METHODS
Global (14 hospitals, nine countries, four continents) randomized clinical trial was conducted in consecutive patients with suspected sarcoidosis stage I/II presenting between May 2015 and August 2017. Using an endobronchial ultrasound (EBUS) scope, patients were randomized to EBUS or endoscopic ultrasound (EUS)-B-guided nodal sampling, and to 22- or 25-G ProCore needle aspiration (2 × 2 factorial design). Granuloma detection rate was the primary study endpoint. Final diagnosis was based on cytology/pathology outcomes and clinical/radiological follow-up at 6 months.
RESULTS
A total of 358 patients were randomized: 185 patients to EBUS-transbronchial needle aspiration (EBUS-TBNA) and 173 to EUS-B-fine-needle aspiration (FNA). Final diagnosis was sarcoidosis in 306 patients (86%). Granuloma detection rate was 70% (130/185; 95% CI, 63-76) for EBUS-TBNA and 68% (118/173; 95% CI, 61-75) for EUS-B-FNA (p = 0.67). Sensitivity for diagnosing sarcoidosis was 78% (129/165; 95% CI, 71-84) for EBUS-TBNA and 82% (115/141; 95% CI, 74-87) for EUS-B-FNA (p = 0.46). There was no significant difference between the two needle types in granuloma detection rate or sensitivity.
CONCLUSION
Granuloma detection rate of mediastinal/hilar nodes by endosonography in patients with suspected sarcoidosis stage I/II is high and similar for EBUS and EUS-B. These findings imply that both diagnostic tests can be safely and universally used in suspected sarcoidosis patients.

Identifiants

pubmed: 34792268
doi: 10.1111/resp.14182
pmc: PMC9299594
doi:

Banques de données

ClinicalTrials.gov
['NCT02540694']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

152-160

Informations de copyright

© 2021 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.

Références

Respir Med. 2013 Jun;107(6):897-903
pubmed: 23490223
Endoscopy. 2012 Oct;44(10):928-33
pubmed: 22826157
Lancet Respir Med. 2016 Dec;4(12):960-968
pubmed: 27773666
Eur Respir J. 2010 Jul;36(1):28-32
pubmed: 19926733
Sarcoidosis Vasc Diffuse Lung Dis. 2004 Jun;21(2):147-51
pubmed: 15281436
Chest. 2014 Sep;146(3):530-532
pubmed: 25180715
Respir Res. 2013 May 10;14:50
pubmed: 23663438
Endoscopy. 2010 Mar;42(3):213-7
pubmed: 20195990
Respiration. 2013;85(2):137-43
pubmed: 23234838
Eur Respir J. 2015 Oct;46(4):1140-9
pubmed: 26160875
Respir Med. 2012 Jun;106(6):883-92
pubmed: 22417738
Lancet. 2014 Mar 29;383(9923):1155-67
pubmed: 24090799
Clin Respir J. 2020 Nov;14(11):1076-1082
pubmed: 32748463
Eur Respir J. 1999 Oct;14(4):735-7
pubmed: 10573213
J Thorac Cardiovasc Surg. 2012 Nov;144(5):1276-7; author reply 1277
pubmed: 23079018
BMJ. 2015 Oct 28;351:h5527
pubmed: 26511519
Chest. 2015 May;147(5):1259-1266
pubmed: 25275701
Respirology. 2015 Feb;20(2):226-34
pubmed: 25477156
Lancet Respir Med. 2018 May;6(5):389-402
pubmed: 29625772
Respirology. 2022 Feb;27(2):152-160
pubmed: 34792268
Chest. 2009 Aug;136(2):340-346
pubmed: 19188547
Chest. 2000 Oct;118(4):928-35
pubmed: 11035658
Expert Rev Med Devices. 2021 Feb;18(2):211-216
pubmed: 33435733
Eur Respir J. 2005 Mar;25(3):405-9
pubmed: 15738281
JAMA. 2013 Jun 19;309(23):2457-64
pubmed: 23780458
Chest. 2014 Sep;146(3):547-556
pubmed: 24481031
J Thorac Cardiovasc Surg. 2008 Apr;135(4):837-42
pubmed: 18374764
Am J Respir Crit Care Med. 2020 Apr 15;201(8):e26-e51
pubmed: 32293205

Auteurs

Laurence M M Crombag (LMM)

Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Kirsten Mooij-Kalverda (K)

Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Artur Szlubowski (A)

Endoscopy Unit, Pulmonary Hospital, Zakopane, Poland.

Maciej Gnass (M)

Endoscopy Unit, John Paul II Hospital, Kraków, Poland.

Kurt G Tournoy (KG)

Department of Respiratory Medicine, Onze-Lieve-Vrouw Ziekenhuis, Aalst, Belgium.
Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

Jiayuan Sun (J)

Department of Respiratory Endoscopy and Interventional Pulmonology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.

Masahide Oki (M)

Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Maarten K Ninaber (MK)

Department of Respiratory Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Daniel P Steinfort (DP)

Department of Respiratory Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia.

Barton R Jennings (BR)

Department of Respiratory Medicine, Monash Health, Clayton, Victoria, Australia.

Moishe Liberman (M)

Division of Thoracic Surgery, University of Montreal, CR-CHUM, Montreal, Québec, Canada.

Semra Bilaceroglu (S)

Department of Respiratory Medicine, Health Sciences University, Izmir, Turkey.
Dr. Suat Seren Training and Research Hospital for Thoracic Medicine and Surgery, Yenişehir Mahallesi, Izmir, Turkey.

Peter I Bonta (PI)

Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Daniël A Korevaar (DA)

Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Rocco Trisolini (R)

Interventional Pulmonology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Jouke T Annema (JT)

Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH